

# Anti-*Toxoplasma gondii* antibodies attach to mouse cancer cell lines but not normal mouse lymphocytes

FERESHTEH MOHAMADI<sup>1</sup>, MAHSHID SHAKIBAPOUR<sup>1</sup>, SEYEDEH MARYAM SHARAFI<sup>2</sup>,  
ALI REZA ANDALIB<sup>3</sup>, SEPIDEH TOLOUEI<sup>1</sup> and HOSSEIN YOUSOFI DARANI<sup>1,4</sup>

<sup>1</sup>Department of Medical Parasitology and Mycology, Isfahan University of Medical Sciences; <sup>2</sup>Environment Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease; <sup>3</sup>Department of Immunology; <sup>4</sup>Cancer Prevention Research Centre, Isfahan University of Medical Sciences, Isfahan 8179498861, Iran

Received January 24, 2018; Accepted January 4, 2019

DOI: 10.3892/br.2019.1186

**Abstract.** *Toxoplasma gondii* (*T. gondii*) is prevalent intracellular parasite and a cause of worldwide infection in the human population. An inhibitory effect of this parasite on cancer growth has been demonstrated in cell culture and animal models. To determine whether the anticancer activities of *T. gondii* are associated with host immune response, in the current study the reactivity of anti-*T. gondii* antiserum with the surface of cancer cell lines was investigated. Anti-*T. gondii* antibodies were raised in rabbit and the reaction of this antiserum in comparison with other anti-parasite antisera (anti-*T. vaginalis*, anti-hydatid cyst fluid, anti-protoscolices antigens) with mouse melanoma or breast cancer cells lines was investigated using flow cytometry. Anti-*T. gondii* antiserum reacted markedly with the surface of mouse melanoma and breast cancer cells, and less so with the normal mouse spleen lymphocytes. Meanwhile, the other anti-parasite antisera did not react strongly with the surface of cancer cells compared with normal mouse spleen lymphocytes. In summary, it has been demonstrated herein that anti-*T. gondii* antiserum may selectively react with the surface of mouse cancer cells but not with normal mouse spleen lymphocytes. Therefore, further study on anti-*Toxoplasma* antibodies may be useful for directing the application of selective drug delivery in cancer treatment.

## Introduction

*Toxoplasma gondii* (*T. gondii*) is a protozoan parasite that infects approximately 1/3 of the human population worldwide (1). Anticancer activities of this parasite have been demonstrated in previous studies (2-4). Notably, it has been observed that

non-replicating *T. gondii* reverses tumor associated immunosuppression (5). Antitumor effects of *T. gondii* antigens in a murine sarcoma 180 tumor model have also been demonstrated (4). In another study, Balb/c inbred mice were injected with *T. gondii* antigens and then challenged with WEHI-164 fibrosarcoma cells, and significant inhibition of tumor growth was observed (6). In other work Choo *et al* (2) injected mice with *T. gondii* antigens and observed that malignant glioma growth was inhibited significantly in comparison with a control group. Kim *et al* (3) challenged two groups of mice with Lewis lung carcinoma, and infected one with *T. gondii* as an experimental group. They observed that survival rate was significantly increased in the parasite-injected mice. Additionally, angiogenesis in the experimental group was notably inhibited (3). In other work, it has been demonstrated that intradermal injection of *T. gondii* stimulated a potent antitumor immune response *in vivo* (7). In this regard it has also been shown that *T. gondii* is able to generate therapeutic antitumor immunity against ovarian cancer (8). Besides *T. gondii*, anticancer activities of other parasites including *Trypanosoma cruzi* (9), malaria parasite (10) and hydatid cyst [larval stage of *Echinococcus granulosus* (*E. granulosus*)] (11-13) have also been reported. The mechanisms underlying the anticancer effects of parasites are not well defined. However, it has been suggested that the immune response raised by the parasites may nonspecifically affect the growth of cancer. For instance, it has been demonstrated that *Trypanosoma cruzi* (*T. cruzi*) is able to elicit a protective immune response against colon and mammary cancers (9). The existence of antibody against *T. cruzi* in mouse was associated with inhibition of tumor growth *in vivo* (14). In another study, it was demonstrated that cell-mediated immunity had a role in antitumor activity of *T. cruzi* (15). In this regard, the presence of common antigens between cancers and certain parasites has been reported (16-18). To identify some of the mechanisms of the anticancer activities of parasites, in the present work a reaction panel of anti-parasite antisera with the surface of mouse melanoma and breast cancer cell lines was investigated.

---

*Correspondence to:* Professor Hossein Yousofi Darani, Department of Medical Parasitology and Mycology, Isfahan University of Medical Sciences, 2 Hezarjereb street, Isfahan 817948859, Iran  
E-mail: yousofidarani@gmail.com

**Key words:** antibodies, breast cancer, cell surface, melanoma, *Toxoplasma gondii*

## Materials and methods

**Antigen preparation.** *T. gondii* purified tachyzoites were purchased from the Pasture Institute, Tehran, Iran. The

tachyzoites were sonicated in PBS, centrifuged for 2 min at 600 x g at room temperature, and the supernatant containing *T. gondii* antigen was maintained at -20°C. *Trichomonas vaginalis* (*T. vaginalis*) parasites maintained in liquid nitrogen from the Department of Parasitology, Isfahan University of Medical Sciences (Isfahan, Iran) were cultured in TYIS medium (produced in-house) and the antigen prepared as described in our previous work (19). Briefly, the parasites were harvested from culture medium, washed three times and sonicated, and *T. vaginalis* crude antigen was kept at -20°C. Sheep lungs or livers infected with hydatid cysts were obtained from slaughtered sheep in Fasaran slaughter house in Isfahan, Iran. Hydatid cyst fluid was then aspirated and examined under a light microscope. Fluid exhibiting the presence of protoscolices was then centrifuged for 2 min at 600 x g and the supernatant containing hydatid cyst fluid antigen was stored at -20°C. The packed protoscolices were also sonicated in PBS, centrifuged for 2 min at 600 x g and the supernatant stored as protoscolices antigen.

**Cell culture.** Mouse melanoma (B16F10) and breast (4T1) cancer cell lines were purchased from the Pasture Institute. The cells were cultured in RPMI-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) with a humidity of 70% and 5.0% CO<sub>2</sub> as previously mentioned (20). Normal lymphocytes were isolated from normal mouse spleens and prepared for further experimentation.

**Animal experiments.** Rabbits and mice were used in the current study, which were purchased from the Pasture Institute. A total of 6 female Balb/c, inbred, 2-month-old mice were used to prepare spleen cells. For this purpose, the mice were euthanized by intraperitoneal injection of 250 mg/kg body weight pentobarbital (Sigma, 3636 under sterile conditions and their spleens removed. Subsequently, the spleen cells were extracted, counted and their viability checked by using trypan blue staining. To prepare cells, spleens were removed from scarified mice and transferred to a Petri Dish containing Isotonic saline. Spleens were then minced using a Scalpel blade and the mixture was passed through a four-layered gauze to remove large debris. Isotonic saline containing cells were then washed twice with isotonic saline and centrifuged at 600 x g for 2 min at room temperature. Subsequently, cells were further suspended in isotonic saline. To stain cells with Trypan blue (Merck, 50 µl prepared cells was mixed with 50 µl Trypan blue stain at room temperature. Following 15 min, one drop of mixed cells with trypan blue was applied to a Neubauer slide (HBG, Germany) and counted using light microscope (magnification, x400).

**Four month-old male rabbits were used to raise antibodies against parasites antigens.** The animals were maintained in an appropriate animal research facility and mice kept in groups of six per cage (rabbits one/cage) and fed with clean food and water. The rabbits were housed at 20-25°C with a humidity of 70-80% with a 12 h light/dark cycle. The animal research protocols of the present study were approved by Isfahan University of Medical Sciences Ethics Committee with approval number IR.mui.REC.1394.824.

**Preparation of rabbit antisera.** Volumes of 1 ml containing 2 mg of the different parasite antigens and sonicated breast and

melanoma cancer cells were emulsified in the same volume (1 ml for each antigen) of Freund's adjuvant (Sigma-Aldrich; Merck KGaA) at room temperature and each antigen injected subcutaneously into a male 4-month-old, white New Zealand rabbit (n=5 in total). Injections were repeated fortnightly. In all rabbits, complete Freund's adjuvant was used for the first injections and incomplete Freund's adjuvant for the boosters. Following the third booster, 1 ml blood samples from the ear vein of each rabbit were collected. To prepare sera, the blood samples were centrifuged at 3,000 x g for 5 min at room temperature. The sera were then checked for the presence of specific antibodies using home-made ELISA tests as described in our previous study (20). In those rabbits with a high titer (optical density >1.5) of antibodies, the last booster was injected into each rabbit and then blood samples were collected and the sera kept at -20°C until use. For the injection of rabbits or bleeding no anesthesia method was used. However, following final bleeding the rabbits were euthanized by intravenous injection of 150 mg/kg pentobarbital.

For ELISA, 96 wells plates were coated with the antigens (*T. gondii*, *T. vaginalis* or hydatid cyst protoscolices crude antigens) diluted 1:20 with carbonate buffer. Following overnight incubation at 37°C, the plates were blocked with 1% bovine albumin (Merck KGaA) and then washed with sodium chloride buffer containing 0.05% Tween-20, and then diluted (1:100) antisera were added and incubated at 37°C for 1 h. The plates were then washed and a secondary antibody (A6154; Sigma-Aldrich) was added and incubated at 37°C for 1 h. Finally, following washing, the plates were incubated with the chromogenic substrate and the optical density of wells was read at 450 nm using an ELISA reader (Kbiokit-ELx800).

**Reaction of antisera with the cancer cell lines.** Mouse cancer cells were harvested from culture medium and normal lymphocytes obtained from normal mouse spleens. All the cells were washed with PBS and incubated for 1 hour at 37°C with different antisera (1:100) which raised in rabbits against different mentioned antigens, namely anti-*T. gondii*, anti-*T. vaginalis*, anti-hydatid cyst fluid, anti-protoscolices antigens, anti-melanoma cells, anti-breast cancer cells or normal rabbit serum primary antibodies. After 1 h, the cells were washed with sodium chloride buffer containing 0.05% Tween-20, and secondary antibodies conjugated with fluorescein isothiocyanate (Donkey anti-rabbit IgG BioLegend, Inc., San Diego, CA, USA; 406403; 1:1,000) were applied in the dark at 4°C for 1 h. Following the last washing of the test tubes, cells were analyzed using a flow cytometer. BD Cell Quest Pro software version 6 (BD Biosciences, San Jose, CA, USA) was used for analysis.

**Statistical analysis.** The experiments were repeated three times and data are presented as the mean ± standard deviation. A linear mixed model test was used for statistical analysis. In comparison of means, P<0.05 was considered to indicate significance.

## Results

**Reaction of anti-*Toxoplasma* antibodies with surface of B16F10 melanoma cells.** The reaction of antiserum against

Table I. Results of flow cytometry analysis (M2 cell percentage of total cells) indicating the level of reaction of different antisera with the surface of mouse melanoma cancer cells (B16F10) and mouse normal spleen cells.

	Anti-melanoma (B16F10) antiserum	Anti- <i>Toxoplasma gondii</i> antiserum	Normal rabbit serum	Background fluorescence
B16F10	10.28±0.49	11.14±1.48 <sup>a</sup>	1.91±0.31	1.11
Spleen cell	-	9.32±0.21	7.79±0.79	3.18

<sup>a</sup>P<0.05 B16F10 cells vs. spleen cells.




Figure 1. Reaction of antisera against mouse melanoma cancer cells, normal rabbit serum and *Toxoplasma gondii* with the surface of live melanoma cancer cells. M1 and M2 indicate cells that were not reactive or reactive with the treated antiserum, respectively.




Figure 2. Reaction of antisera against breast cancer cells, normal rabbit serum and *Toxoplasma gondii* with the surface of live breast cancer cells. M1 and M2 indicate cells that were not reactive or reactive with the treated antiserum, respectively.

*T. gondii* and normal rabbit serum with the surface of mouse melanoma cells was investigated. Anti-*T. gondii* antiserum exhibited a marked reaction with melanoma cells, while the reaction of normal rabbit serum was weak. In this experiment, anti-melanoma cell antiserum was used as a positive control and normal rabbit serum as a negative control (Fig. 1 and Table I). Analysis of experimental repeats indicated that the difference in M2 (reactive) cells between the anti-*T. gondii* antiserum and normal rabbit serum groups was statistically significant (P<0.05).

**Reaction of anti-*Toxoplasma* antibodies with surface of 4T1 breast cancer cells.** The reaction of antisera against *T. gondii* and normal rabbit serum with the surface of mouse breast cancer cells was investigated. Again, *T. gondii* antiserum

exhibited a strong reaction with breast cancer cells while the reaction of normal rabbit serum was weak. Anti-breast cancer cell antisera were used as a positive control and normal rabbit serum as a negative control (Fig. 2 and Table II). When the experiment was repeated, the difference in M2 cells between the anti-*T. gondii* antiserum and normal rabbit serum groups was statistically significant (P<0.05).

**Reaction of anti-*Toxoplasma* antibodies with surface of mouse normal spleen lymphocytes.** The reaction of anti-*T. gondii* antiserum and normal rabbit serum with the surface of mouse normal spleen lymphocytes was investigated. The results revealed that the reaction of anti-*Toxoplasma* antibodies with melanoma cells was greater than the reaction with mouse normal lymphocytes. However, the reaction of normal rabbit

Table II. Results of flow cytometry analysis (M2 cell percentage of total cells) indicating the level of reaction of different antisera with the surface of mouse breast cancer cells (4T1) and mouse normal spleen cells.

	Anti-4T1 antiserum	Anti- <i>Toxoplasma gondii</i> antiserum	Normal rabbit serum	Background fluorescence
4T1	62.14±7.97	81.77±22.2 <sup>a</sup>	2.06±0.69	0.17
Spleen cells	-	7.79±0.79	9.32±0.21	3.18

<sup>a</sup>P<0.05 vs. spleen cells.

Table III. Results of flow cytometry analysis (M2 cell percentage of total cells) indicating reaction of antisera against *Trichomonas vaginalis* and hydatid cyst crude protoscolices antigen with the surface of breast cancer cells, melanoma cancer cells or normal mouse spleen lymphocytes.

	Anti- <i>Trichomonas vaginalis</i> antiserum	Anti-hydatid cyst protoscolices antiserum	Background fluorescence intensity
Melanoma cancer cells	3.74±0.74	2.11±0.35	1.11±0.14
Breast cancer cells	5.75±1.23	3.64±0.82	0.17±0.09
Normal mouse spleen lymphocytes	11.23±2.39	9.43±1.97	3.18±0.68




Figure 3. Reaction of normal rabbit serum and antisera against *Toxoplasma gondii* with the surface of normal mouse spleen lymphocytes. Background fluorescence has been shown as a control. M1 and M2 indicate cells that were not reactive or reactive with the treated antiserum, respectively.

serum with mouse normal lymphocytes was greater than the reaction with melanoma cells (Fig. 3 and Tables I and II).

*Reaction of anti-T. vaginalis* and anti-protoscolices antibodies with surface of melanoma, breast cancer or mouse normal spleen lymphocytes. To determine if antisera against different parasites exhibited a reaction similar to that of anti-*T. gondii* antiserum, the reactions of antisera against *T. vaginalis* and hydatid cyst crude protoscolices antigen with the surface of breast cancer cells, melanoma cells and normal mouse spleen lymphocytes were investigated. The results revealed no statistically significant differences in the reactions of the sera with cancer cells compared with spleen lymphocytes (Table III).

## Discussion

Results of the present work indicated that anti-*T. gondii* antiserum selectively reacts with the surface of murine melanoma and breast cancer cells and not with normal mouse spleen lymphocytes. Additionally, the results

revealed that this selective reactivity did not occur with other anti-parasitic antisera including anti-*T. vaginalis* or anti-hydatid cyst protoscolices antigen. This is a notable finding as through selective attachment of anti-*T. gondii* antibodies to cancer cells, these antibodies may be valuable carriers of cancer immunotherapeutics. In this regard, Salanti *et al* (21) demonstrated that a glycosaminoglycan protein of *Plasmodium falciparum* selectively attached to cancer cells, and they proposed that this protein may be a viable candidate for cancer immunotherapy.

Reaction of anti-*Toxoplasma* antibodies with the surface of breast and melanoma cancer cells implies that there are shared epitopes on the surface of cancer cells and *Toxoplasma* antigens. In this context, existence of common antigens between certain parasites and cancers has been documented (16,17). The majority of these antigens are specific mucin glycoproteins, which have important roles in the metastasis of cancer cells (22) and in the interaction of parasites and their hosts. For instance, expression of tumor-associated antigen in adult and larval stages of *E. granulosus* has been observed. Additionally,

cross-reaction of the sera of cancer patients with 40 and 27 kDa bands of hydatid cyst antigens has been demonstrated (18,23).

The effect elicited by cross-reaction of antibodies raised against *Toxoplasma* with epitopes on the surface of cancer cells remained undetermined in the present study. However, the attachment of the antibody to the cancer cells surface may exert some lethal effects on the cancer cells. For instance, it has been shown that *Trypanosoma cruzi* antigens stimulated protective immunity against colon and mammary cancers (9). Alternatively, this cross-reaction may render the cancer cells vulnerable to the complement system. In this regard it has been reported that complexes of antigen-antibody are able to activate the complement system (24).

In previous years there has been considerable focus on enhancing antibody activity through conjugation with cytotoxic drugs (25-28). Thus, with further work it may be possible to conjugate humanized purified anti-*Toxoplasma* monoclonal antibodies to a cytotoxic drug to improve its suitability for site-selective drug delivery. Such anti-*Toxoplasma* monoclonal antibodies may have the advantage of being effective against different cancers. It has been demonstrated that drug targeting may improve the efficacy of therapy and reduce side effects associated with drugs (29). Immunohistochemistry is now recommended to investigate the reaction of anti-*Toxoplasma* antibodies with human breast cancer tissues.

One of the main problems in the treatment of cancer is that most of the drugs used to target cancer cells are also cytotoxic to normal tissues. Attempts have been made to overcome this problem by coupling anticancer drugs to antibodies which have some degree of specificity for cancer antigens. In this regard there are numerous patents regarding use of antibodies for drug delivery. For instance, in a patented method by Sahin *et al* (30), monoclonal antibodies against claudin-18 were used for the treatment of different cancers. Patil *et al* (31) also conjugated a polymeric acid platform to a monoclonal antibody to enable specific drug delivery to treat different cancers. Furthermore, conjugation of an antibody with a cytotoxin or an enzyme for the selective treatment of cancers has been proposed (32).

Through further study it may be possible to conjugate humanized purified anti-*Toxoplasma* monoclonal antibodies to a drug for selective treatment of certain cancers. Tumor-associated antigens (TAAs) are expressed by tumor cells and can be recognized by the immune system. Most known TAAs have been found to be expressed by melanoma cancer cells, and few TAAs have been recognized in other tumors (33). TAAs exhibit poor immunogenicity, which results in lack of a sufficient immune response to control cancer growth (34,35). It has been demonstrated that vaccination with TAA peptides generally fails to induce a specific immune response in mice (36). Immunization with parasite-derived antigens, which have shared epitopes with TAAs, may overcome this disadvantage and induce a high degree of protective immunity. In this regard, it has been observed that for virally induced tumors, prophylactic vaccination with synthetic peptides was effective in animal models (37,38), whereas for non-virally induced tumors this vaccination was less effective (39,40). Thus, induction of a strong immune response may be one of the critical advantages of immunotherapy with parasitic antigens.

In conclusion, in the present study it was indicated that anti-*Toxoplasma* antiserum selectively reacts with the surface of mouse cancer cells but not with normal mouse spleen lymphocytes. With further work these selectively binding antibodies may be a useful tool in cancer immunotherapy.

### Acknowledgements

The present study was prepared from thesis by a PhD student (Mrs Mahshid Shakibapour) and an MSc student (Miss Fereshteh Mohamadi) from Isfahan University of Medical Sciences.

### Funding

The present work was supported by a grant (grant no. 3953009) from Isfahan University of Medical Sciences (Isfahan, Iran).

### Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

### Authors' contributions

FM and MS performed the experiments. SS performed the experiments and wrote the first draft of the manuscript. AA consulted immunohistochemical procedures. ST assisted with experiments. HD supervised experiments and prepared final version of the manuscript.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. John DT, Petri WA, Markell EK, and Voge M: Markell and Voge's Medical Parasitology. 9th edition. Elsevier Health Sciences, St. Louis, 2006.
2. Choo JD, Lee JS, Kang JS, Lee HS, Yeom JY and Lee YH: Inhibitory effects of *Toxoplasma* antigen on proliferation and invasion of human glioma cells. *J Korean Neurosurg Soc* 37: 129-136, 2005.
3. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH and Lee YH: Inhibition of Lewis lung carcinoma growth by *Toxoplasma gondii* through induction of Th1 immune responses and inhibition of angiogenesis. *J Korean Med Sci* 22: S38-S46, 2007.
4. Pyo KH, Jung BK, Chai JY and Shin EH: Suppressed CD31 expression in sarcoma-180 tumors after injection with *Toxoplasma gondii* lysate antigen in BALB/c mice. *Korean J Parasitol* 48: 171-174, 2010.
5. Fox BA, Sanders KL and Bzik DJ: Non-replicating *Toxoplasma gondii* reverses tumor-associated immunosuppression. *Oncoimmunology* 2: e26296, 2013.

6. Darani HY, Shirzad H, Mansoori F, Zabardast N and Mahmoodzadeh M: Effects of *Toxoplasma gondii* and *Toxocara canis* antigens on WEHI-164 fibrosarcoma growth in a mouse model. *Korean J Parasitol* 47: 175-177, 2009.
7. Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, *et al*: Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated *Toxoplasma gondii* protects against rechallenge. *J Immunol* 190: 469-478, 2013.
8. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S and Bzik DJ: Avirulent *Toxoplasma gondii* generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. *Cancer Res* 73: 3842-3851, 2013.
9. Ubillos L, Freire T, Berriel E, Chiribao ML, Chiale C, Festari MF, Medeiros A, Mazal D, Rondán M, Bollati-Fogolín M, *et al*: *Trypanosoma cruzi* extracts elicit protective immune response against chemically induced colon and mammary cancers. *Int J Cancer* 138: 1719-1731, 2016.
10. Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, Chen L, Zhong N and Chen X: Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. *PLoS One* 6: e24407, 2011.
11. Chookami MB, Sharafi SM, Sefiddashti RR, Jafari R, Bahadoran M, Pestechian N and Yousofi Darani H: Effect of two hydatid cyst antigens on the growth of melanoma cancer in C57/black mice. *J Parasit Dis* 40: 1170-1173, 2016.
12. Berriel E, Russo S, Monin L, Festari MF, Berois N, Fernández G, Freire T and Osinaga E: Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. *ScientificWorldJournal* 230176, 2013.
13. Karadayi S, Arslan S, Sumer Z, Turan M, Sumer H and Karadayi K: Does hydatid disease have protective effects against lung cancer? *Mol Biol Rep* 40: 4701-4704, 2013.
14. Kallinikova VD, Batmonkh Ts, Kosobokova EN, Pakhorukova LV, Ogloblina TA, Kravtsov EG, Karpenko LP and Matekin PV: Antibodies against *Trypanosoma cruzi* in intact mice and their oncoprotective effect. *Med Parazitol (Mosk)* 1: 11-15, 2008 (In Russian).
15. Zenina AV, Kravtsov EG, Tsetsegsaikhan B, Yashina NV, Dalin MV, Karpenko LP, Sheklakova LA and Kallinikova V: The study of immunological component in antitumor effect of *Trypanosoma cruzi*. *Bull Exp Biol Med* 145: 352-354, 2008.
16. Ubillos L, Medeiros A, Cancela M, Casaravilla C, Saldaña J, Domínguez L, Carmona C, Le Pendu J and Osinaga E: Characterization of the carcinoma-associated Tk antigen in helminth parasites. *Exp Parasitol* 116: 129-136, 2007.
17. Thors C, Jansson B, Helin H and Linder E: Thomsen-Friedenreich oncofetal antigen in *Schistosoma mansoni*: Localization and immunogenicity in experimental mouse infection. *Parasitology* 132: 73-81, 2006.
18. Daneshpour S, Bahadoran M, Hejazi SH, Eskandarian AA, Mahmoudzadeh M and Darani HY: Common antigens between hydatid cyst and cancers. *Adv Biomed Res* 5: 9, 2016.
19. Darani HY, Ahmadi F, Zabardast N, Yousefi HA and Shirzad H: Development of a latex agglutination test as a simple and rapid method for diagnosis of *Trichomonas vaginalis* infection. *Avicenna J Med Biotechnol* 2: 63-66, 2010.
20. Sharafi SM, Shirzad H, Khanahmad H, Ataei B and Darani HY: Monoclonal antibodies production against a 40 KDa band of hydatid cyst fluid. *Recent Pat Biotechnol* 12: 57-64, 2018.
21. Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, *et al*: Targeting human cancer by a glycosaminoglycan binding malaria protein. *Cancer Cell* 28: 500-514, 2015.
22. Baldus SE, Engelmann K and Hanisch FG: MUC1 and the MUCs: A family of human mucins with impact in cancer biology. *Crit Rev Clin Lab Sci* 41: 189-231, 2004.
23. Sharafi SM, Rafiei R, Rafiei R, Hadipour M, Shirzad H, Khanahmad H and Darani HY: A Nonglycosylated 27 kDa molecule as common antigen between human breast cancer and *Echinococcus granulosus* hydatid cyst wall. *Adv Breast Cancer Res* 5: 90-95, 2016.
24. Porter R and Reid K: Activation of the complement system by antibody-antigen complexes: the classical pathway. *Advances in protein chemistry*. *Adv Protein Chem* 33: 1-71, 1979.
25. Chari RV: Targeted cancer therapy: Conferring specificity to cytotoxic drugs. *Acc Chem Res* 41: 98-107, 2008.
26. Damle NK: Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. *Expert Opin Biol Ther* 4: 1445-1452, 2004.
27. Kovtun YV and Goldmacher VS: Cell killing by antibody-drug conjugates. *Cancer Lett* 255: 232-240, 2007.
28. Wu AM and Senter PD: Arming antibodies: Prospects and challenges for immunoconjugates. *Nat Biotechnol* 23: 1137-1146, 2005.
29. Trail PA, King HD and Dubowchik GM: Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. *Cancer Immunol Immunother* 52: 328-337, 2003.
30. Sahin U, Türeci Ö, Usener D, Fritz S, Uherek C, Brandenburg G, Geppert HG, Schroeder Anja K and Thiel P: Monoclonal antibodies against claudin-18 for treatment of cancer. *Google Patents EP 2311879 A2*. Filed November 24 2005; issued April 20, 2011.
31. Patil R, Holler E, Black KL and Ljubimova JY: Drug delivery of Temozolomide for systemic based treatment of cancer. *Google Patents US8785371B2*. Filed December 10, 2009; issued November 28, 2017.
32. Lallatin NC: Monoclonal antibodies to human thymidine kinase to treat cancer. *Google Patents*, 2013.
33. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM and Anichini A: Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? *J Natl Cancer Inst* 94: 805-818, 2002.
34. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, *et al*: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 80: 219-230, 1999.
35. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C and Celis E: A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. *J Immunother* 22: 431-440, 1999.
36. Valmori D, Fonteneau J-F, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC and Romero P: Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. *J Immunol* 160: 1750-1758, 1998.
37. Schulz M, Zinkernagel RM and Hengartner H: Peptide-induced antiviral protection by cytotoxic T cells. *Proc Natl Acad Sci USA* 88: 991-993, 1991.
38. Kast WM, Roux L, Curren J, Blom HJ, Voordouw AC, Meloen RH, Kolakofsky D and Melief CJ: Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. *Proc Natl Acad Sci USA* 88: 2283-2287, 1991.
39. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G and Eisenbach L: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. *Nat Med* 1: 1179-1183, 1995.
40. Noguchi Y, Chen YT and Old LJ: A mouse mutant p53 product recognized by CD4<sup>+</sup> and CD8<sup>+</sup> T cells. *Proc Natl Acad Sci USA* 91: 3171-3175, 1994.